Shanghai Fosun Pharmaceutical (Group) Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Fosun Pharmaceutical (Group) Company Limited with three other
companies in this sector in China:
Shenzhen Neptunus Bioengineer
sales of 13.61 billion Chinese Renmimbi [US$1.97 billion]
of which 84%
was Pharmaceutical Distribution),
Harbin Pharmaceutical Group Company Limited
(14.13 billion Chinese Renmimbi [US$2.05 billion]
of which 64%
was Medicine Trade), and
Tasly Pharmaceutical Group Company Limited
(13.95 billion Chinese Renmimbi [US$2.02 billion]
of which 51%
was Medicine Commerce).
During the year ended December of 2016, sales at
Shanghai Fosun Pharmaceutical (Group) Company Limited were 14.51 billion Chinese Renmimbi (US$2.11 billion).
increase of 16.0%
versus 2015, when the company's sales were 12.50 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shanghai Fosun Pharmaceutical (Group) Company Limited
(and since 2011, sales have increased a total of 124%).
Sales of Healthcare saw an increase
21.7% in 2016, from
1.38 billion Chinese Renmimbi to 1.68 billion Chinese Renmimbi.
Not all segments of Shanghai Fosun Pharmaceutical (Group) Company Limited experienced an increase in sales in 2016:
sales of Other Business Operations fell 29.5% to 26.62 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).